These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J; J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730 [TBL] [Abstract][Full Text] [Related]
5. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. Ribera E; Azuaje C; Lopez RM; Diaz M; Feijoo M; Pou L; Crespo M; Curran A; Ocaña I; Pahissa A AIDS; 2006 May; 20(8):1131-9. PubMed ID: 16691064 [TBL] [Abstract][Full Text] [Related]
6. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
7. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA; BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812 [TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. Malan N; Su J; Mancini M; Yang R; Wirtz V; Absalon J; McGrath D; AIDS Care; 2010 Jun; 22(6):677-86. PubMed ID: 20467943 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E; Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947 [TBL] [Abstract][Full Text] [Related]
11. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study. Keiser PH; Nassar N Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861 [TBL] [Abstract][Full Text] [Related]
13. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946 [TBL] [Abstract][Full Text] [Related]
14. Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients. Bickel M; Bodtländer A; Knecht GK; Stephan C; von Hentig N; Kurowski M; Gute P; Klauke S; Lutz T J Antimicrob Chemother; 2009 Dec; 64(6):1260-4. PubMed ID: 19776037 [TBL] [Abstract][Full Text] [Related]
15. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905 [TBL] [Abstract][Full Text] [Related]
16. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096 [TBL] [Abstract][Full Text] [Related]
17. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336 [TBL] [Abstract][Full Text] [Related]